Ranbaxy to market Daiichi Sankyo products in Mexico
05 Oct 2009
Daiichi Sankyo and Ranbaxy Laboratories today said that the apanese pharmaceutical firm's portfolio would be commercialised in Mexico through a recently created marketing division within Ranbaxy's mexican subsidiary, Ranbaxy Mexico S.A. de C.V.
Atul Sobti, CEO and managing director of Ranbaxy, said, "The creation of a Daiichi Sankyo division within Ranbaxy - Mexico marks our first endeavour in creating a dedicated marketing arm for Daiichi Sankyo's portfolio of innovator products. Our understanding of Latin American markets and local presence pave the way for an efficient and immediate market entry for Daiichi Sankyo, while priming the channel for the launch of Ranbaxy speciality products in the future."
Daiichi Sankyo and Ranbaxy are leveraging mutual synergies generated through the hybrid business mode for the first time in a Latin American market.
This hybrid model will enable the two companies to leverage their respective strengths in the dominant prescription segment, through the newly created division, while continuing expansion in the rapidly evolving generics market.
With an estimated population of 107 million people, Mexico is Latin America's second biggest market after Brazil, with annual pharma salesof about $10.4 billion, hat also rank the country as the world's 11th largest pharma market.
Ranbaxy Mexico S.A de C.V. has a strong portfolio of generics and its products are available at leading generic customers and large Pharmacy chains. Additionally, it has licensing arrangements with leading Multinational companies.
Takashi Shoda, president and CEO of Daiichi Sankyo, said, "We are dedicated to realise various synergies through our hybrid business model which enables both companies to fully realize their strengths. I am pleased to announce one of such synergy, our commitment to directly introduce Daiichi Sankyo products in Mexico leveraging Ranbaxy's strong platform. I believe our products will offer an excellent therapy option to the doctors and patients in Mexico."
.webp)
